tbuckley/cabot-search huggingface dataset:
Destabilization of Fatty Acid Synthase by Acetylation Inhibits <i>De Novo</i> Lipogenesis and Tumor Cell Growth
Authors: Huai-Peng Lin, Zhou-Li Cheng, Ruo-Yu He, Lei Song, Meng-Xin Tian, Li-Sha Zhou, Beezly S. Groh, Wei-Ren Liu, Min-Biao Ji, Chen Ding, Ying-Hong Shi, Kun-Liang Guan, Dan Ye, Yue Xiong
Journal: Cancer Research (2016)

Abstract Fatty acid synthase (FASN) is the terminal enzyme in de novo lipogenesis and plays a key role in cell proliferation. Pharmacologic inhibitors of FASN are being evaluated in clinical trials for treatment of cancer, obesity, and other diseases. Here, we report a previously unknown mechanism of FASN regulation involving its acetylation by KAT8 and its deacetylation by HDAC3. FASN acetylation promoted its degradation via the ubiquitin–proteasome pathway. FASN acetylation enhanced its association with the E3 ubiquitin ligase TRIM21. Acetylation destabilized FASN and resulted in decreased de novo lipogenesis and tumor cell growth. FASN acetylation was frequently reduced in human hepatocellular carcinoma samples, which correlated with increased HDAC3 expression and FASN protein levels. Our results suggest opportunities to target FASN acetylation as an anticancer strategy. Cancer Res; 76(23); 6924–36. ©2016 AACR.
TCT-322 Utility of J-Chronic Total Occlusion (CTO) Score as a Predictor of Successful Percutaneous Coronary Intervention of CTO: Comparison of Coronary Computed Tomography and Coronary Angiography
Authors: Akiko Fujino, Satoru Otsuji, Katsuyuki Hasegawa, Toyohiro Arita, Shin Takiuchi, Masanori Yabuki, Motoaki Ibuki, Katsuaki Asano, Shinya Nagayama, Kasumi Ishibuchi, Toshikazu Kashiyama, Rui Ishii, Yorihiko Higashino
Journal: Journal of the American College of Cardiology (2015)
Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences
Authors: E Waanders, B Scheijen, M C J Jongmans, H Venselaar, S V van Reijmersdal, A H A van Dijk, A Pastorczak, R D A Weren, C E van der Schoot, M van de Vorst, E Sonneveld, N Hoogerbrugge, V H J van der Velden, B Gruhn, P M Hoogerbrugge, J J M van Dongen, A Geurts van Kessel, F N van Leeuwen, R P Kuiper
Journal: Leukemia (2016)
TCT-686 Impact of Aortic Valve Type on Cerebral Ischemic Lesions in DW-MRI after TAVR
Authors: Klaudija Bijuklic, Timo Haselbach, Julian Witt, Korff Krause, Lorenz Hansen, Ralf Gehrkens, Friedrich-Christian Rieß, Joachim Schofer
Journal: Journal of the American College of Cardiology (2015)
A pooled analysis of observational data evaluating usage and clinical outcomes of erythropoietic agents
Authors: F. Papatheofanis, K. Fahrbach, T. L. Mark, T. Chiang, D. Frame, R. Y. Suruki, R. Scheye, M. Drielick, L. Nalysnyk
Journal: Journal of Clinical Oncology (2004)

6144 Background: Randomized trials designed to establish a dose conversion ratio (DCR) between epoetin alfa (EPO) and darbepoetin alfa (DARB) in chemotherapy-related anemia (CRA) have yet to be published. One trial is underway (Jakubowski Blood. 2003;102:107b). A DCR determines the amount of each agent required to produce the same effect on hemoglobin (Hb). Since the necessity for a DCR exists, estimation must be based on available data. Methods: Four large, similarly designed, multicenter observational studies were conducted to compare usage and Hb outcomes of EPO and DARB in patients (pts) with CRA ([EPO/DARB pts]; Study 1:1,267/892; Study 2: 812/340; Study 3: 527/478; Study 4: 2,952/184). Records across clinical and administrative data systems of pts receiving care in outpatient practice settings were reviewed. Pts were required to have a cancer diagnosis, be at least 18 years old, and have a record of treatment with EPO or DARB for CRA (Hb less than or equal to 11g/dL). Results: Baseline characteristics: age, gender, weight, tumor type, chemotherapy, Hb, transfusion use, and iron supplementation across groups were all similar within each study. Mean anemia treatment duration was about 8 weeks ([EPO/DARB days]; Study 1: 57/68; Study 2: 56/59; Study 3: 58/62; Study 4: 50/60). Mean cumulative doses were similar across studies ([EPO U/DARB mcg]; Study 1: 286,040/1,036; Study 2: 282,234/1,178; Study 3: 254,774/1,055; Study 4: 257,814/947). Early Hb rise independent of observed transfusion was significantly greater for EPO vs DARB ([EPO -DARB, week 4 Hb, g/dL]; Study 1: 0.22; Study 2: 0.43; Study 3: 0.30; Study 4: 0.19). Cumulative Hb effect over 12 weeks, assessed by area under the curve (AUC) for Hb change, was also greater for EPO vs DARB ([EPO-DARB AUC12, g/dL]; Study 1: 2.7; Study 2: 4.4; Study 3: 3.2; Study 4: 0.4). An overall pooled DCR of 263 U of EPO to 1 mcg of DARB was calculated. After adjustment for differences in effectiveness, a pooled DCR of 212 U of EPO to 1 mcg of DARB was calculated. Conclusions: An earlier and greater Hb effect was observed for EPO compared with DARB. Four studies, representing about 7,500 pts, support a DCR less than or equal to 260:1 of EPO:DARB. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Ortho Biotech Products, L.P.
TCT-666 A Comparison Between New Generation And First Generation Transcatheter Aortic Valve Implantation (TAVI) Devices: A Single Centre Experience
Authors: Neil Ruparelia, Azeem Latib, Francesco Giannini, Filippo Figini, Nicola Buzzatti, Antonio Mangieri, Damiano Regazzoli, Stefano Stella, Alessandro Sticchi, Eustachio Agricola, Michele De Bonis, Fabrizio Monaco, Pietro Spagnolo, Alaide Chieffo, Matteo Montorfano, Ottavio Alfieri, Antonio Colombo
Journal: Journal of the American College of Cardiology (2015)
Alternative Polyadenylation in Triple-Negative Breast Tumors Allows NRAS and c-JUN to Bypass PUMILIO Posttranscriptional Regulation
Authors: Wayne O. Miles, Antonio Lembo, Angela Volorio, Elena Brachtel, Bin Tian, Dennis Sgroi, Paolo Provero, Nicholas Dyson
Journal: Cancer Research (2016)

Alternative polyadenylation (APA) is a process that changes the posttranscriptional regulation and translation potential of mRNAs via addition or deletion of 3' untranslated region (3' UTR) sequences. To identify posttranscriptional-regulatory events affected by APA in breast tumors, tumor datasets were analyzed for recurrent APA events. Motif mapping of the changed 3' UTR regions found that APA-mediated removal of Pumilio regulatory elements (PRE) was unusually common. Breast tumor subtype-specific APA profiling identified triple-negative breast tumors as having the highest levels of APA. To determine the frequency of these events, an independent cohort of triple-negative breast tumors and normal breast tissue was analyzed for APA. APA-mediated shortening of NRAS and c-JUN was seen frequently, and this correlated with changes in the expression of downstream targets. mRNA stability and luciferase assays demonstrated APA-dependent alterations in RNA and protein levels of affected candidate genes. Examination of clinical parameters of these tumors found those with APA of NRAS and c-JUN to be smaller and less proliferative, but more invasive than non-APA tumors. RT-PCR profiling identified elevated levels of polyadenylation factor CSTF3 in tumors with APA. Overexpression of CSTF3 was common in triple-negative breast cancer cell lines, and elevated CSTF3 levels were sufficient to induce APA of NRAS and c-JUN. Our results support the hypothesis that PRE-containing mRNAs are disproportionately affected by APA, primarily due to high sequence similarity in the motifs utilized by polyadenylation machinery and the PUM complex. Cancer Res; 76(24); 7231-41. ©2016 AACR.
First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial.
Authors: J. Liang, M. Ahn, J. Kang, Q. Xiu, Y. Chen, C. Yang, N. Scheuer, C. Linn, M. Orlando
Journal: Journal of Clinical Oncology (2010)

7591 Background: Asian, n/smkr NSCLC pts show more favorable clinical course and improved outcomes when treated with EGFR-TKIs or chemo, particularly in presence of EGFR mutations (mut). In unknown EGFR mut status pts, optimal selection/integration of both modalities is unclear. This trial compared first-line sequential (seq) txt with PC followed by either G or P. Methods: Asian, n/smkr, chemonaive, stage IIIB/IV NSCLC and ECOG PS ≤1 pts, of unknown EGFR mut status, were randomized to Arm A (4 cycles: P[500 mg/m2] + C[75 mg/m2] q3 wks followed by G [250 mg/d]) or Arm B (induction chemo per Arm A followed by P [500 mg/m2] q3 wks [+C, max 2 additional cycles]). While progression-free survival (PFS) was calculated from randomization, the primary objective was a comparison during the seq phase only (ie, from cycle 5) by a time-dependent Cox model. Tissue collection for EGFR mut analysis was optional. Results: Primary endpoint analysis results are presented. Between (btwn) Feb-Nov 2007, 70 pts from China, Korea and Taiwan received induction PC. Baseline characteristics were balanced btwn arms. 49 pts (70.0%) received seq txt (n=25 G; n=24 P), while 21 pts (30.0%) discontinued during induction. The primary endpoint indicates pts on seq G have significantly lower risk of progression and PFS overall indicates a trend favoring Arm A. Response was not statistically different btwn txt arms, yet duration of response was improved in Arm A. Survival was consistently higher for Arm B pts. No significant difference was observed btwn txt arms for grade 3/4/5 toxicities. Conclusions: Pts receiving first-line PC followed by seq G showed prolonged PFS, in excess of 9 mths. OS, although immature, is encouraging regardless of seq txt choice. Evaluation of txt sequence according to EGFR mut status in NSCLC pts is warranted. Arm A Arm B Induction PC (N=39)Seq G (N=25) Induction PC (N=31)Seq P (N=24) HR (95% CI); p value PFS HR seq phase only 0.194 (0.075, 0.502); <0.001 PFS HR overall 0.533 (0.272, 1.044); 0.067 PFS median mths (95% CI) 9.95 (5.85, 16.49) 6.83 (5.78, 7.98) Overall survival (OS), % 12 mths 74.8 93.3 24 mths 59.6 71.1 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Lilly Lilly
Comorbidity Indices Predict Survival Among Elderly Patients with Acute Myelogenous Leukemia but Do Not Aid in Selecting Between Traditional Induction Chemotherapy and 5-Azacytidine Treatment.
Authors: Stuart L. Goldberg, Aisha Masood, Jayshree Shah, Jack W. Hsu, Neelesh Rastogi, Kevin Lu, Genique Stanislaus, Ken Granholm, Elizabeth Jones, Sora Limor, Jimmy Nieves, Alyona Weinstein, William Marrero, Anita Vargas, Sara Hyman, Yesenia Llerena, Michelle Hanrahan, Jamie L. Yaniga
Journal: Blood (2009)
Neoadjuvant chemoradiation therapy with capecitabine (CAP) plus oxaliplatin (OX) in rectal cancer: Final results of a phase II study
Authors: C. Carlomagno, F. D'Armiento, A. Farella, L. Cannella, A. De Stefano, M. Colantuoni, S. Alfieri, M. Marra, G. Totaro, S. Pepe
Journal: Journal of Clinical Oncology (2008)

4090 Background: Pre-operative chemoradiation is nowadays a standard treatment for rectal cancer patients (pts). CAP plus OX (CAP-OX) are synergistic with radiotherapy (RT) and active in colorectal neoplasms. Methods: Two cycles of CAP 825 mg/sqm bid (days 1–14) and OX 50 mg/sqm (days 1 & 8) every 3 weeks were given concomitantly with pelvic conformal RT (1.8 Gy daily up to 45 Gy in 5 weeks). Pts were eligible if they had a ≥ T3 rectal mass (as measured by endorectal ultrasound) or involved peri-rectal lymph-nodes (uN+). The pathologic tumor response was defined according to the Tumor Regression Grade (TRG) scale. A 2-steps design for phase II trials was adopted: 18 pts (≥ 3 TRG1) for first step and a total of 43 pts (≥ 8 TRG1) were estimated to meet the primary endpoint that was the activity of preoperative RT plus CAP-OX on TRG. Results: As of July ‘07, 45 pts were enrolled (29 M, 16 F) with a median age of 64.4 years (range 42–79). All pts completed the neoadjuvant chemoradiotherapy program and are evaluable for toxicity: G1–2 gastrointestinal adverse events were observed in 25 pts; only 1 pt experienced G3 vomiting and 1 pt G3 diarrhea; 7 pts had G1 peripheral neuropathy. Hematological toxicity (G1-G2) was observed in 6 pts. Local toxicity (G1) was experienced by 22 pts; G2 proctitis and anal pain occurred in only 2 pts. After treatment the uT3-uT4 rate was 68.7% (versus 88.8% before) and only 25.8% of pts were uN+ (versus 57.7% before treatment). 42 pts have been operated (1 refused surgery, 1 developed lung metastases and 1 deceased for reasons other than toxicity or tumor progression): low anterior resection was performed in 29 pts (69%), abdominal perineal resection in 12 pts (28.6%) and transanal resection in 1 pt. Complete pathological response (TRG1) was observed in 10 pts (23.8%); TRG2 in 18 pts (42.9%); TRG3 in 11 pts (26.2%); TRG4 in 3 pts (7.1%). As of Dec 31, 2007, 7 pts recurred: 5 pts with distance metastases (1 peritoneum, 1 brain, 1 nodes, 1 liver, 1 lung); 1 pts with local recurrence; 1 pts with both liver and local recurrence. Conclusions: The combination of CAP-OX with pelvic radiotherapy as pre- operative treatment for rectal cancer is active, producing a remarkable rate of complete or near-complete pathological responses, and overall well tolerated. No significant financial relationships to disclose.
A Patient with Chronic Lymphocytic Leukemia and Bone Localization: A Case Report
Authors: Iolanda Donatella Vincelli, Patrizia Cufari, Said al Sayyad, Carmelo Tuscano, Natale Porta, Claudio di Cristofano, Vincenzo Petrozza, Demetrio Aricò, Caterina Stelitano, Stefania Ciolli, Grazia Iaria, Angela Violi, Francesca Ronco
Journal: Blood (2015)
Prognostic Implications of Pri-Mir-320a Expression in Acute Myeloid Leukemia Patients
Authors: Taqiuddine Gaber, Marius Bill, Madlen Jentzsch, Karoline Schubert, Heike Weidner, Laura Kloss, Laura Schmalbrock, Bonifacio Lynn, Kathrin Wildenberger, Wolfram Pönisch, Vladan Vucinic, Georg-Nikolaus Franke, Thoralf Lange, Michael Cross, Gerhard Behre, Dietger Niederwieser, Sebastian Schwind
Journal: Blood (2014)
Longitudinal prospective assessment of sleep disturbance in breast cancer.
Authors: S. D. Sanford, L. I. Wagner, J. L. Beaumont, Z. Butt, J. J. Sweet, D. Cella
Journal: Journal of Clinical Oncology (2010)

9101 Background: Cross-sectional data suggest that individuals with breast cancer experience significant sleep disturbance pre-, during, and post-chemotherapy and/or radiation therapy. To date, longitudinal data indicate sleep disturbances cumulatively worsen over the course of chemotherapy. The objectives of this study were to prospectively examine the longitudinal trajectory of sleep quality in breast cancer patients before, during, and after adjuvant chemotherapy and to evaluate the relationship between sleep quality and health-related quality of life. Methods: Sleep quality was assessed with the Pittsburgh Sleep Quality Index (PSQI) and quality of life was assessed with the Functional Assessment of Cancer Therapy (FACT-G). Assessments were completed at baseline immediately prior to chemotherapy, cycle 4 day 1, and 6 months after baseline. Results: Participants (N=80) were primarily women (97.5%) with Stage II (69.0%) breast cancer. Age ranged from 29 to 71 years (M=49.7; SD=9.2). In our sample, 65.8% of patients reported significantly impaired sleep pre- treatment, 60.5% at cycle 4 day 1, and 48.5% at 6 months using the PSQI total score. Most patients either experience impaired sleep (37.5%) or normal sleep (21.9%) throughout the course of the study. A mixed effects model revealed no significant differences in PSQI total score or subscale scores across time points with one exception. The daytime functioning subscale scores were significantly worse during treatment compared to before and after chemotherapy (p<0.01). FACT-G scores were negatively correlated with PSQI total scores across all time points (rho = −0.46; −0.41; −0.45; p<0.001). Conclusions: Results suggest that sleep disturbances were highly prevalent across the continuum of care for persons with breast cancer. Daytime dysfunction increased during chemotherapy and poorer sleep quality was highly correlated with lower health-related quality of life. Most individuals demonstrating sleep problems pre-chemotherapy continue to do so after completion of treatment. Early identification and treatment of sleep disturbances and daytime impairment may minimize disruption to health-related quality of life and lessen symptom burden associated with chemotherapy. No significant financial relationships to disclose.
GW27-e1247 Analyses the relationship between of the occurrence of cardiovascular events and the operation of fracture of pelvis
Authors: Xu Tianfa, Yanhua Xie, Xianshang Zeng, Ke Zhan, Yangchun Zhang, Junyong Hu, Shiming Yu, Zhanchun Li, Jianhua Liu
Journal: Journal of the American College of Cardiology (2016)
TCT-285 Radiation dose reduction in the cardiac catheterization laboratory utilising a novel protocol
Authors: Jurado-Roman Alfonso, Ignacio Sanchez-Perez, Fernando Lozano, Maria T. Lopez-Lluva, Andrea Moreno-Arciniegas, Natalia Pinilla-Echeverri, Pilar Agudo-Quilez
Journal: Journal of the American College of Cardiology (2015)
A reclassification of Myelodysplastic Syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall Survival. A retrospective analysis of 49 Patients
Authors: Jaroslav Cermak, Dana Mikulenková, Jana Brezinova, Kyra Michalova
Journal: Blood (2012)
TCT-42 Accounting for right atrial pressure in the calculation of Fractional Flow Reserve (FFR) significantly increases the number of physiologically significant stenoses suitable for PCI
Authors: Christopher Cook, Yousif Ahmad, Ricardo Petraco, Sukhjinder S. Nijjer, Rasha Al-Lamee, Mauro Echavarria-Pinto, Jason M. Tarkin, Carlo Di Mario, Iqbal S. Malik, Javier Escaned, Sayan Sen, Justin E. Davies
Journal: Journal of the American College of Cardiology (2015)
Practical guidance for mismatch repair-deficiency testing in endometrial cancer
Authors: E. Stelloo, A.M.L. Jansen, E.M. Osse, R.A. Nout, C.L. Creutzberg, D. Ruano, D.N. Church, H. Morreau, V.T.H.B.M. Smit, T. van Wezel, T. Bosse
Journal: Annals of Oncology (2016)
Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.
Authors: Guy Laurent, Sylvie Lafaye de Micheaux, Philippe Solal-Celigny, Pierre Soubeyran, Vincent Delwail, Hervé Ghesquières, Catherine Thieblemont, Eric Jourdan, Lucile Beautier, Fabien Audibert, Patrick Squiban, Helene Sicard, Jean-Francois Rossi
Journal: Blood (2009)
TCT-583 Comparison of the NOBORI Biolimus-Eluting Stent and the XIENCE/PROMUS Cobalt Chronium Everolimus-Eluting Stent in Patients With De novo Long Coronary Artery Lesions
Authors: Takashi Hiromasa, Shoichi Kuramitsu, Hiroyuki Jinnouchi, Takashi Morinaga, Yohei Kobayashi, Takenori Domei, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando, Masakiyo Nobuyoshi
Journal: Journal of the American College of Cardiology (2015)
A Bispecific Protein Targeting the NKG2D Receptor on Natural Killer Cells: In Vitro and In Vivo activity of ULBP2-CEA
Authors: Marie Madlener, Achim Rothe, Ron Jachimowicz, Katrin S. Reiners, Sampurna Chatterjee, Roland Ullrich, Paul Yazaki, Andreas Engert, Elke Pogge von Strandmann
Journal: Blood (2010)
Acute visual loss after ipilimumab treatment for metastatic melanoma
Authors: Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher
Journal: Journal for ImmunoTherapy of Cancer (2016)

<h3>Background</h3> Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs). <h3>Case presentation</h3> Here we describe a patient treated with ipilimumab who experienced known IrAEs, including hypophysitis, as well as a profound vision loss due to optic neuritis. There are rare reports of optic neuritis occurring as an adverse event associated with ipilimumab treatment. Furthermore, the patient experienced multiple complications from high dose steroids used to manage his IrAEs. <h3>Conclusions</h3> This case highlights the need for recognition of atypical immune mediated processes associated with newer checkpoint inhibitor therapies including ipilimumab.
A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia.
Authors: Pellegrino Musto, Maria Teresa Petrucci, Fortunato Morabito, Francesco Nobile, Fiorella D'Auria, Rosa Lerose, Anna Sparano, Antonia Zonno, Vincenzo Callea, Anna Levi, Carla Mazzone, Giuseppe Pietrantuono, Maria Carmen Martorelli, Antonino Neri, Paola Omedè, Sara Bringhen, Michele Cavo, Mario Boccadoro, Antonio Palumbo
Journal: Blood (2009)
SSRIs double the risk of suicide and violence in healthy adults
Authors: Ingrid Torjesen
Journal: BMJ (2016)

Selective serotonin and serotonin-norepinephrine (noradrenaline) reuptake inhibitors double the risk of suicide and violence in healthy adults with no signs of a mental disorder, a systematic review has found.

The review, published in the Journal of the Royal Society of Medicine , is the first to analyse trials of these antidepressants in healthy adults.1 Researchers from the Nordic Cochrane Centre and University of Copenhagen in Denmark identified 130 double blind, randomised placebo controlled trials through PubMed and Embase and 29 …
Progressive alterations in multipotent hematopoietic progenitors underlie lymphoid cell loss in aging
Authors: Kira Young, Sneha Borikar, Rebecca Bell, Lauren Kuffler, Vivek Philip, Jennifer J. Trowbridge
Journal: The Journal of Experimental Medicine (2016)

Declining immune function with age is associated with reduced lymphoid output of hematopoietic stem cells (HSCs). Currently, there is poor understanding of changes with age in the heterogeneous multipotent progenitor (MPP) cell compartment, which is long lived and responsible for dynamically regulating output of mature hematopoietic cells. In this study, we observe an early and progressive loss of lymphoid-primed MPP cells (LMPP/MPP4) with aging, concomitant with expansion of HSCs. Transcriptome and in vitro functional analyses at the single-cell level reveal a concurrent increase in cycling of aging LMPP/MPP4 with loss of lymphoid priming and differentiation potential. Impaired lymphoid differentiation potential of aged LMPP/MPP4 is not rescued by transplantation into a young bone marrow microenvironment, demonstrating cell-autonomous changes in the MPP compartment with aging. These results pinpoint an age and cellular compartment to focus further interrogation of the drivers of lymphoid cell loss with aging.
TCT-570 3-Year Clinical Outcome of the DUTCH PEERS (TWENTE II) Randomized Trial: Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Versus Platinum-Chromium Everolimus-Eluting Promus Element Stents in All-Comer Patients
Authors: Clemens von Birgelen, Liefke C. van der Heijden, Marlies M. Kok, Peter W. Danse, Gillian A. Jessurun, Raymond Hautvast, Marc Hartmann, Melvyn Tjon Joe Gin, Alexander Schramm, Hans W. Louwerenburg, Marije M. Löwik, Gerard C. Linssen, Carine J. Doggen, Martin G. Stoel
Journal: Journal of the American College of Cardiology (2015)
Acute Neck Pain Progressing to Hemiparesis With Brain and Spinal Cord Lesions
Authors: David Gabelia, Slaven Pikija, Abdul Rahman Al-Schameri
Journal: JAMA Neurology (2016)

A man had weakness in the distal right hand and leg; and sudden, severe neck pain that progressed to neck stiffness and shoulder pain; magnetic resonance imaging revealed abnormal signals throughout the brain and a lesion at the level of the fifth cervical vertebra. What is your diagnosis?
Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes
Authors: Anita Roy, Larissa Lordier, Stefania Mazzi, Yunhua Chang, Valérie Lapierre, Jérome Larghero, Najet Debili, Hana Raslova, William Vainchenker
Journal: Blood (2016)